Accreditations & Certifications
Blueprint Genetics Laboratory located in Finland is a CLIA-certified (#99D2092375) laboratory and accredited by the College of American Pathologists (CAP #9257331) and by FINAS Finnish Accreditation Service, laboratory no. T292, accreditation requirement SFS-EN ISO 15189:2013. Detailed information about the scope is available on the FINAS website.
We offer genetic testing globally covering North and South America, Europe, Australia and the Middle East.
Blueprint Genetics CES Platform and Blueprint Genetics WES Platform, manufactured by Blueprint Genetics Oy are CE marked in-vitro diagnostic medical devices. Samples that are sent to our Helsinki laboratory for whole-exome sequencing, panel, single-gene, or variant-specific testing are run on the CE marked in-vitro diagnostic medical devices.
Blueprint Genetics Finland licensure:
Name |
Number |
Valid until |
CAP accreditation |
#9257331 | Apr 22, 2026 |
ISO 15189 Accredited by FINAS |
No. T292 | Feb 2, 2028 |
CLIA – Clinical Laboratory Improvement Amendments |
#99D2092375 | Apr 20, 2025 |
State of California License |
#CDS00800637 | Apr 30, 2025 |
State of Maryland License |
#2409 | Non-expiring |
State of Pennsylvania License |
#34897 | Aug 15, 2025 |
State of Rhode Island License |
#LCO01312 | Dec 30, 2024 |
Blueprint Genetics Marlborough, MA licensure:
Name |
Number |
Valid until |
CAP accreditation |
#3733701 | Feb 1, 2025 |
MTS / CLIA – Clinical Laboratory Improvement Amendments |
#22D0069726 | Nov 16, 2024 |
Please see more information about our quality control and accreditation through the following link: